Nurix Therapeutics Inc
$ 17.04
-2.68%
20 Apr - close price
- Market Cap 1,810,636,000 USD
- Current Price $ 17.04
- High / Low $ 17.40 / 16.98
- Stock P/E N/A
- Book Value 4.65
- EPS -3.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.61 %
- 52 Week High 22.50
- 52 Week Low 8.20
About
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Analyst Target Price
$30.24
Quarterly Earnings
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-14 | 2026-01-28 | 2025-10-09 | 2025-07-09 | 2025-04-08 | 2025-02-13 | 2024-10-11 | 2024-07-11 | 2024-04-10 | 2024-02-15 | 2023-10-12 | 2023-07-13 |
| Reported EPS | -0.79 | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.45 |
| Estimated EPS | -0.8295 | -0.92 | -0.83 | -0.714 | -0.7614 | -0.6689 | -0.71 | -0.63 | -0.8 | -0.57 | -0.76 | -0.56 |
| Surprise | 0.0395 | 0.1 | -0.2 | 0.194 | 0.0914 | -0.0811 | 0.04 | -0.08 | 0.04 | -0.2 | 0.08 | 0.11 |
| Surprise Percentage | 4.7619% | 10.8696% | -24.0964% | 27.1709% | 12.0042% | -12.1244% | 5.6338% | -12.6984% | 5% | -35.0877% | 10.5263% | 19.6429% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NRIX
2026-04-21 06:39:19
Wells Fargo and Stifel have revised their price targets for Nurix Therapeutics (NRIX) in early April 2026, following the biopharmaceutical firm's recent financial reports and clinical updates. Wells Fargo lowered its target to $28 from $29 but maintained an Overweight rating, citing undervaluation in immunology and inflammation and a key data milestone expected in Q1 2026. Stifel reduced its target to $34 from $35, keeping a Buy rating, due to reported GAAP net loss exceeding expectations.
2026-04-19 21:10:02
Nurix Therapeutics (NRIX) experienced a 9.2% stock price increase despite reporting significantly lower Q1 2026 revenue of US$6.25 million, down from US$18.45 million, and a wider net loss of US$87.17 million. This performance highlights the company's continuous investment in its protein degradation platform and early oncology pipeline, underscoring the importance of liquidity and future milestones from partners like Gilead and Sanofi. Although the stock has seen a strong annual increase, investors are now more focused on cash burn and funding plans, especially given the company's elevated valuation.
2026-04-19 20:12:00
Wells Fargo has lowered its price target on Nurix Therapeutics (NRIX) to $28 from $29, while maintaining an Overweight rating, citing the "underappreciated" opportunity of bexdeg in immunology and inflammation. Separately, Stifel also reduced its price target to $34 from $35 and kept a Buy rating due to Nurix reporting a wider-than-expected GAAP net loss. Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory conditions and cancer.
2026-04-19 19:12:00
Wells Fargo has lowered its price target on Nurix Therapeutics (NRIX) to $28 from $29, while maintaining an Overweight rating. The firm notes that while management is progressing with bexdeg's chronic lymphocytic leukemia trials, the potential of bexdeg in immunology and inflammation remains undervalued. Stifel also updated its rating, reducing the price target to $34 from $35, citing a wider-than-expected GAAP net loss for Nurix Therapeutics.
2026-04-18 12:39:59
This article identifies Nurix Therapeutics, Inc. (NASDAQ:NRIX) as one of the top low-priced biotech stocks worth investing in, highlighting recent analyst ratings and price target adjustments from Wells Fargo and Stifel. Despite reporting a wider-than-expected GAAP net loss, the company is recognized for its clinical-stage biopharmaceutical work in developing therapies for inflammatory conditions, cancer, and other diseases. Analysts maintain an Overweight/Buy rating, with Wells Fargo emphasizing the underappreciated opportunity for bexdeg in immunology and inflammation.
2026-04-12 10:10:11
Nurix Therapeutics (NRIX) has shown mixed share performance, with recent short-term weakness despite a strong one-year return. The company's current Price-to-Sales ratio of 23.1x is considered overvalued compared to its estimated fair level and industry averages, especially given its significant net losses. This suggests that the current share price reflects high expectations and leaves it sensitive to setbacks.
